Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland
Year: 2025
Type: article
Abstract: The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. The recommendations are the result of extensive interdisciplinary discussions in a group of Swiss dementia experts from August 2023 until December 2024. They reflect the opinion of all societies involved in the diagnosis and treatment of dementia patients in Switzerland. Special emphasis is given to aspects that are specific to the Swiss landscape, including recommendations for infrastructural and personnel standards for institutions aiming to administer anti-amyloid mAbs in Switzerland.
Source: Neurodegenerative Diseases
DOI: 10.1159/000545799
Authors: Ansgar Felbecker, Olivier Rouaud, Aurelien Lathuiliere, Gilles Allali, Marc Sollberger, Tatjana Meyer-Heim, Andreas U. Monsch, Karl-Olof Lövblad, Stefanie Becker, Nadège Barro-Belaygues, Julius Popp, Markus Bürge, Kathrin Lindheimer, Anton Gietl, Hans H. Jung, Dan Georgescu, Rafael Meyer, Giovanni B. Frisoni
Institutions: University Hospital of Bern, Centre Hospitalier Universitaire Vaudois, University of Lausanne, University Hospital of Geneva, University Hospital of Basel, Alzheimer Schweiz, Spitalzentrum Centre hospitalier Biel- Bienne, University of Zurich, Klinik Hirslanden, GastroZentrum Hirslanden Zürich, Psychiatrische Universitätsklinik Zürich, University Hospital Zurich
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: National Science Foundation, Eli Lilly and Company, Biogen, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Eisai, Novo Nordisk, Hôpitaux Universitaires de Genève, Université de Genève, H. Lundbeck A/S, Fondation Segré, Horizon 2020 Framework Programme, Novo Nordisk Pharma
OpenAlex ID: W4409414319